FrancophonIA/ELRC3.0 huggingface dataset:
English: This means that the proteins are fixed onto a compound containing aluminium, to stimulate a better immune response.
Estonian: See tähendab, et valgud on parema immuunvastuse tekitamiseks kinnitatud alumiiniumiühendile.
English: The most common side effects with Bexsero in children up to 10 years of age (seen in more than 1 patient in 10) are eating disorders, sleepiness, unusual crying, headache, diarrhoea, vomiting, rash, arthralgia (joint pain), fever and irritability as well as tenderness, swelling, hardness and redness of the skin at the injection site.
Estonian: Kuni 10-aastastel lastel on Bexsero kõige sagedamad kõrvalnähud (esinenud enam kui 1 patsiendil 10st) söömishäired, unisus, põhjuseta nutmine, peavalu, kõhulahtisus, oksendamine, lööve, liigesevalu, palavik ja ärrituvus ning süstekoha valulikkus, turse, kõvenemine ja nahapunetus.
English: It is given by deep injection into a muscle, preferably into the shoulder muscle, or into the thigh muscle in children under two years old.
Estonian: Vaktsiin manustatakse sügava lihasesisese süstena, eelistatavalt õlavarde deltalihasesse või alla 2-aastastel lastel reielihasesse.
English: How does Bexsero work?
Estonian: Kuidas Bexsero toimib?
English: Bexsero is a vaccine used to protect individuals from the age of two months against invasive meningococcal disease caused by one group of the bacterium Neisseria meningitidis (group B).
Estonian: Bexsero on vaktsiin, mida kasutatakse vähemalt 2-kuu vanuste isikute kaitsmiseks bakteri Neisseria meningitidis ühe rühma (B-rühma) põhjustatud invasiivse meningokokkinfektsiooni eest.
English: For the full list of side effects and restrictions with Bexsero, see the package leaflet.
Estonian: Bexsero kohta teatatud kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
English: How is Bexsero used?
Estonian: Kuidas Bexserot kasutatakse?
English: What benefits of Bexsero have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Bexsero kasulikkus?
English: The most common side effects with Bexsero in adolescents from 11 years of age and adults (seen in more than 1 patient in 10) are headache, nausea (feeling sick) and malaise (feeling unwell), myalgia (muscle pain) and arthralgia as well as pain, swelling, hardness and redness of the skin at the injection site.
Estonian: Täiskasvanutel ja vähemalt 11-aastastel noorukitel on Bexsero kõige sagedamad kõrvalnähud (esinenud enam kui 1 patsiendil 10st) peavalu, iiveldus ja halb enesetunne, lihasevalu ja liigesevalu ning süstekoha valu, turse, kõvenemine ja nahapunetus.
English: Bexsero has been shown to produce a robust immune response to N. meningitidis group B and the risks are acceptable.
Estonian: Bexsero tekitab tõendatult tugeva immuunvastuse N. meningitidis B-rühma bakterite vastu ning riskid on vastuvõetavad.
English: This study was extended to look at the effects of giving a booster dose of Bexsero at or after 12 months of age to children who had already received Bexsero in early infancy, compared with giving two ‘catch-up' doses to those who had not.
Estonian: Uuringut pikendati, et uurida Bexsero korduvannuse mõju 12-kuustel või vanematel lastel, kes olid Bexserot juba saanud varases imikueas, võrreldes seda kahe annuse manustamisega lastel, kes ei olnud Bexserot varem saanud.
English: Bexsero contains parts of the bacteria N. meningitidis group B.
Estonian: Bexsero sisaldab N. meningitidis B-rühma bakterite osi.
English: The effects of giving one, two or three doses of Bexsero (at intervals of at least one month) were compared with giving placebo (a dummy treatment).
Estonian: Uuringus võrreldi Bexsero ühe, kahe ja kolme annuse mõju (manustatuna vähemalt 1-kuulise vaheajaga) platseeboga (näiv vaktsiin).
English: The study showed that Bexsero was effective at stimulating an immune response to N. meningitidis group B and that two doses were needed to produce an adequate immune response.
Estonian: Uuring tõendas, et Bexsero oli N. meningitidis B-rühma vastase immuunvastuse stimuleerimisel efektiivne ja et adekvaatse immuunvastuse saamiseks on vaja manustada kaks annust.
English: An overview of Bexsero and why it is authorised in the EU
Estonian: Ülevaade ravimist Bexsero ja ELis müügiloa väljastamise põhjendus
English: Bexsero contains four proteins which are found on the surfaces of cells of the N. meningitidis group B bacterium.
Estonian: Bexsero sisaldab N. meningitidis B-rühma bakterite rakkude nelja pinnavalku.
English: The effects of giving three doses of Bexsero at two-month intervals together with other routine infant vaccinations were compared with giving the routine vaccinations alone.
Estonian: Uuringus võrreldi Bexsero kolme annuse manustamist (2-kuulise vaheajaga) koos muude imikute tavavaktsiinidega tavavaktsiinide manustamisega ilma Bexserota.
English: Bexsero is available as a suspension for injection in a pre-filled syringe and can only be obtained with a prescription.
Estonian: Bexserot turustatakse süstesuspensioonina eeltäidetud süstlas.
English: The study showed that Bexsero was effective at stimulating an immune response to N. meningitidis group B. In addition, a single booster dose of Bexsero at 12 months of age produced a stronger immune response in children who had already received Bexsero than the first of two ‘catchup' doses in children of the same age who had not.
Estonian: Peale selle tekitas üks 12kuustele lastele manustatud Bexsero korduvannus tugevama immuunvastuse lastel, kes olid juba saanud Bexserot, kui samas vanuses manustatud esimene kahest annusest lastel, keda ei olnud varem Bexseroga vaktsineeritud.
English: Two main studies showed that Bexsero was effective at stimulating an immune response to N. meningitidis group B. The studies measured the production of protective antibodies which are able to kill the bacteria.
Estonian: Kahes põhiuuringus tõendati, et Bexsero on N. meningitidis B-rühma bakterite vastase immuunvastuse stimuleerimisel efektiivne.
English: Most patients had previously received other medicines but could not continue with them.
Estonian: Enamik patsiente kasutas varem muid ravimeid, kuid ei saanud nende kasutamist jätkata.
English: Patients were treated with Xagrid for up to five years.
Estonian: Patsiente raviti Xagridiga kuni viis aastat.
English: Xagrid was not compared with any other medicines.
Estonian: Xagridit ei võrreldud teiste ravimitega.
English: Further information on Xagrid can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Lisateave Xagridi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: What measures are being taken to ensure the safe and effective use of Xagrid?
Estonian: Mis meetmed võetakse, et tagada Xagridi ohutu ja efektiivne kasutamine?
English: Xagrid (anagrelide) EMA/326376/2018
Estonian: Xagrid (anagreliid) EMA/326376/2018
English: Xagrid received a marketing authorisation valid throughout the EU on 16 November 2004.
Estonian: Xagrid on saanud müügiloa, mis kehtib kogu ELis, 16. novembril 2004.
English: The European Medicines Agency decided that Xagrid's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Euroopa Ravimiamet otsustas, et Xagridi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: Xagrid (anagrelide)
Estonian: Xagrid (anagreliid)
English: Other information about Xagrid
Estonian: Muu teave Xagridi kohta
English: What is Xagrid and what is it used for?
Estonian: Mis on Xagrid ja milleks seda kasutatakse?
English: Xagrid is available as capsules (0.5 mg).
Estonian: Xagridit turustatakse kapslitena (0,5 mg).
English: In the largest study, 67% of the patients with essential thrombocythaemia (628 out of 934), and 66% of those who could not tolerate other treatments or whose condition did not respond to them (480 out of 725) had a complete response to Xagrid.
Estonian: Suurimas uuringus oli patsiente, kellel tekkis Xagridile täielik ravivastus, essentsiaalse trombotsüteemiaga patsientidest 67% (628 patsienti 934st) ja patsientidest, kes ei talunud muid ravimeid või kellel ei tekkinud nendega ravivastust, 66% (480 patsienti 725st).
English: As for all medicines, data on the use of Xagrid are continuously monitored.
Estonian: Nagu kõigi ravimite puhul, teostatakse Xagridi kasutamise kohta pidevat järelevalvet.
English: The recommended starting dose is 1 capsule twice a day.
Estonian: Soovitatav algannus on 1 kapsel kaks korda ööpäevas.
English: The dose can then be increased every week by 1 capsule a day, until the patient's platelet count is below 600 million platelets per millilitre, and ideally between 150 and 400 million/ml (the usual level in healthy people).
Estonian: Annust suurendatakse kord nädalas, iga kord 1 kapsli võrra ööpäevas, kuni trombotsüütide sisaldus patsiendi veres langeb alla 600 miljoni raku milliliitri kohta, ideaaljuhul vahemikku 150-400 miljonit/ml (tervete inimeste normaalsisaldus).
English: In the other three studies, between 60 and 82% of patients had a complete response.
Estonian: Ülejäänud kolmes uuringus oli tekkinud ravivastusega patsiente 60%…82%.
English: The most common side effect with Xagrid (which may affect more than 1 in 10 people) is headache.
Estonian: Xagridi kõige sagedam kõrvalnäht (võib esineda enam kui 1 patsiendil 10st) on peavalu.
English: Side effects reported with Xagrid are carefully evaluated and any necessary action taken to protect patients.
Estonian: Xagridi kõrvalnähte hinnatakse hoolikalt ja patsientide kaitseks rakendatakse vajalikke meetmeid.
English: Xagrid was originally authorised under ‘exceptional circumstances'.
Estonian: Xagridi müügiluba anti esialgu erandlikel asjaoludel.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Xagrid have been included in the summary of product characteristics and the package leaflet.
Estonian: Xagridi ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: This reduces the platelet count, helping to improve symptoms in patients with the disease.
Estonian: See vähendab trombotsüütide sisaldust, aidates parandada patsientide sümptomeid.
English: The main measure of effectiveness was the number of patients who had a ‘complete response', when platelet counts fell either by at least 50% from the start of treatment or to below 600 million/ml.
Estonian: Efektiivsuse põhinäitaja oli nende patsientide arv, kellel tekkis täielik ravivastus, kui trombotsüütide sisaldus vähenes alates ravi algusest vähemalt 50% võrra või alla 600 miljoni/ml.
English: Xagrid must not be used in patients with moderate or severe liver or kidney disease.
Estonian: Xagridit ei tohi kasutada mõõduka või raske neeru- või maksahaigusega patsiendid.
English: Xagrid is used when patients do not respond to or do not tolerate their current treatment, and when they are ‘at risk' because of their age (over 60 years), very high platelet counts or previous clotting problems.
Estonian: Xagridit kasutatakse, kui patsiendil ei teki senise raviga ravivastust või kui ta seda ei talu või kui ta kuulub vanuse (üle 60 a), trombotsüütide väga suure sisalduse või varasemate hüübimisprobleemide tõttu riskirühma.
English: Xagrid contains the active substance anagrelide.
Estonian: Xagrid sisaldab toimeainena anagreliidi.
English: For more information about using Xagrid, see the package leaflet or contact a doctor or a pharmacist.
Estonian: Lisateavet Xagridi kasutamise kohta vt pakendi infolehest või konsulteeri oma arsti või apteekriga.
English: The maximum recommended dose of Xagrid is 5 capsules at a time.
Estonian: Xagridi soovitatav suurim annus on 5 kapslit korraga.
English: Xagrid was effective in lowering platelet counts in four main studies involving patients with various diseases in which the bone marrow produces too many cells.
Estonian: Xagrid oli efektiivne trombotsüütide sisalduse vähendamisel neljas põhiuuringus, milles osalenud patsientidel oli mitmesuguseid haigusi, mille korral tekib luuüdis liiga palju rakke.
English: Xagrid is a medicine used to reduce the number of platelets (components that help the blood to clot) in patients with essential thrombocythaemia (a disease in which there are too many platelets in the blood).
Estonian: Xagrid on ravim, mida kasutatakse trombotsüütide (vereliistakud ehk vererakud, mis aitavad verel hüübida) sisalduse vähendamiseks patsientidel, kellel on essentsiaalne trombotsüteemia (haigus, mille korral veres on liiga palju trombotsüüte).
English: What are the risks associated with Xagrid?
Estonian: Mis riskid Xagridiga kaasnevad?
English: This is because, as a result of the disease's rarity, it had not been possible to obtain full information about it. As the company has supplied the additional information requested, the ‘exceptional circumstances' ended on 11.07.2018.
Estonian: Et ettevõte esitas vajaliku lisateabe, tühistati müügiloa erandlikel asjaoludel väljastatus 11.07.2018.
English: How is Xagrid used?
Estonian: Kuidas Xagridit kasutatakse?
English: Almost 3,000 of the patients in the studies had essential thrombocythaemia, with a platelet count of more than 600 million/ml.
Estonian: Uuringus osalenutest oli ligikaudu 3000 patsiendil essentsiaalne trombotsüteemia trombotsüütide sisaldusega veres üle 600 miljoni/ml.
English: How does Xagrid work?
Estonian: Kuidas Xagrid toimib?
English: In essential thrombocythaemia the bone marrow produces too many platelets.
Estonian: Essentsiaalse trombotsüteemia korral tekib luuüdis liiga palju trombotsüüte.
English: The active substance in Xagrid, anagrelide, blocks the development and growth of cells in the bone marrow called ‘megakaryocytes', which produce platelets.
Estonian: Xagridi toimeaine anagreliid pärsib luuüdis trombotsüüte tekitavate rakkude megakarüotsüütide arengut ja kasvu.
English: For the full list of all side effects of Xagrid, see the package leaflet.
Estonian: Xagridi kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: An overview of Xagrid and why it is authorised in the EU
Estonian: Ülevaade ravimist Xagrid ja ELis müügiloa väljastamise põhjendus
English: Treatment should only be started by a doctor who has experience in the treatment of essential thrombocythaemia.
Estonian: Ravi Xagridiga tohib alustada üksnes essentsiaalse trombotsüteemiaga patsientide ravis kogenud arst.
English: What benefits of Xagrid have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Xagridi kasulikkus?
English: Xagrid can only be obtained with a prescription.
Estonian: Xagrid on retseptiravim.
English: Why is Xagrid authorised in the EU?
Estonian: ELis Xagridile väljastatud müügiloa põhjendus
English: The median age was 54 years.
Estonian: Mediaanvanus oli 54 aastat.
English: ● The other ingredients are:
Estonian: • Teised koostisosad on:
English: Talk to your doctor about the right methods of contraception for you and your partner.
Estonian: Pidage nõu oma arstiga, millised on õiged rasestumisvastased meetodid teile ja teie partnerile.
English: ● This medicine has been prescribed for you only.
Estonian: • Ravim on välja kirjutatud üksnes teile.
English: ● and is advanced.
Estonian: • ja on kaugelearenenud.
English: Dose modification advice is provided in Tables 1 and 2 below.
Estonian: Annuse muutmise soovitused on toodud tabelites 1 ja 2 allpool.
English: Do not give this medicine to children or adolescents under the age of 18 years.
Estonian: Ärge andke seda ravimit lastele ja alla 18-aastastele noorukitele.
English: A risk to the newborn/infant cannot be excluded.
Estonian: Ei saa välistada riski vastsündinule/imikule.
English: There are no available data on patients over 80 years of age.
Estonian: Puuduvad andmed üle 80-aastaste patsientide kohta.
English: The hard capsules should be swallowed whole, and must not be opened or dissolved.
Estonian: Kõvakapslid tuleb neelata tervelt ning neid ei tohi avada ega lahustada.
English: Do not stop taking this medicine without talking to your doctor first.
Estonian: Ärge lõpetage selle ravimi võtmist ilma kõigepealt arstiga nõu pidamata.
English: Contraception, pregnancy, and breast-feeding - information for women Contraception - information for women
Estonian: Rasestumisvastane kaitse, rasedus ja imetamine - teave naistele Rasestumisvastane kaitse - teave naistele
English: Alecensa with food and drink
Estonian: Alecensa koos toidu ja joogiga
English: Take the medicine pack and this leaflet with you.
Estonian: Võtke ravimi pakend ja käesolev infoleht endaga kaasa.
English: The corresponding values for M4 were 217 L/hour and 30.7 hours, respectively.
Estonian: Vastavad väärtused M4 puhul olid 217 l/tunnis ja 30,7 tundi.
English: Extreme body weight (>130 kg)
Estonian: Väga suur kehakaal (> 130 kg)
English: Frequency category (all grades)
Estonian: Esinemissageduse kategooria (kõik raskusastmed)
English: It is used if your lung cancer:
Estonian: Seda kasutatakse juhul, kui teil esinev kopsuvähk:
English: It is important to take Alecensa twice a day for as long as your doctor prescribes it for you.
Estonian: Tähtis on võtta Alecensa't kaks korda päevas senikaua, kui arst seda soovitab.
English: It may also help to shrink your cancer.
Estonian: See võib aidata viia ka vähi kahenemiseni.
English: ● You should not become pregnant while taking this medicine.
Estonian: • Selle ravimi võtmise ajal ei tohi jääda rasedaks.
English: Within each system organ class, undesirable effects are presented in order of decreasing frequency.
Estonian: Igas organsüsteemi klassis on kõrvaltoimed toodud esinemissageduse vähenemise järjekorras.
English: Abnormal forms of this enzyme (due to fault in the gene that makes it) help encourage cancer cell growth.
Estonian: Selle ensüümi ebanormaalsed vormid (vea tõttu seda tootvas geenis) aitavad soodustada vähirakkude kasvu.
English: The safety and efficacy of Alecensa in children and adolescents below 18 years of age have not been established.
Estonian: Alecensa ohutus ja efektiivsus lastel ja noorukitel vanuses alla 18 aasta ei ole tõestatud.
English: Other medicines and Alecensa
Estonian: Muud ravimid ja Alecensa
English: Effects of age, body weight, race and gender
Estonian: Vanuse, kehakaalu, rassi ja soo mõju
English: Aluminium/aluminium (PA/Alu/PVC/Alu) blisters containing 8 hard capsules.
Estonian: Alumiinium/alumiinium (PA/Alu/PVC/Alu) blistrid, mis sisaldavad 8 kõvakapslit.
English: Date of latest renewal: 1 December 2017
Estonian: Müügiloa viimase uuendamise kuupäev: 1. detsember 2017
English: ● if you are allergic to alectinib or any of the other ingredients of this medicine (listed in section 6).
Estonian: • kui olete alektiniibi või selle ravimi mis tahes koostisosade (loetletud lõigus 6) suhtes allergiline.
English: ● You must take Alecensa with food.
Estonian: • Alecensa't peab võtma koos toiduga.
English: Alecensa may slow down or stop the growth of your cancer.
Estonian: Alecensa võib aeglustada või peatada vähi kasvu.
English: DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 16 February 2017
Estonian: ESMASE MÜÜGILOA VÄLJASTAMISE/MÜÜGILOA UUENDAMISE KUUPÄEV Müügiloa esmase väljastamise kuupäev: 16. veebruar 2017
English: Alecensa can cause side effects that you need to tell your doctor about straight away.
Estonian: Alecensa võib põhjustada kõrvaltoimeid, millest tuleb otsekohe rääkida oma arstile.
English: Heart rate and blood pressure should be monitored as clinically indicated.
Estonian: Südame löögisagedust ja vererõhku tuleb mõõta nagu kliiniliselt näidustatud.
English: HDPE bottle with a child-resistant closure and an integrated desiccant.
Estonian: HDPE-pudel lapsekindla sulguriga ja integreeritud kuivatusainega.
English: Grade 2 or Grade 3 (symptomatic, may be severe and medically significant, medical intervention indicated)
Estonian: 2. või 3. raskusastme bradükardiaa (sümptomaatiline, võib olla raske ja meditsiiniliselt oluline, näidustatud on meditsiiniline sekkumine)
English: Thereafter, monitoring should be performed periodically, since events may occur later than 3 months, with more frequent testing in patients who develop aminotransferase and bilirubin elevations.
Estonian: Seejärel peab kontroll toimuma perioodiliselt, sest muutused võivad ilmneda pärast 3 kuu möödumist; sagedamini kontrollitakse patsiente, kellel tekib aminotransferaaside aktiivsuse ja bilirubiinisisalduse suurenemine.
English: Pharmacotherapeutic group: anti-neoplastic agents, protein kinase inhibitor; ATC code: L01XE36.
Estonian: Farmakoterapeutiline rühm: kasvajavastased ained, proteiini kinaasi inhibiitor; ATC-kood: L01XE36.
English: Duration of treatment Treatment with Alecensa should be continued until disease progression or unacceptable toxicity.
Estonian: Ravi Alecensa'ga peab jätkama kuni haiguse progresseerumise või vastuvõetamatu toksilisuse tekkimiseni.
English: System organ class ADRs (MedDRA)
Estonian: Organsüsteemi klass Kõrvaltoimed (MedDRA)
English: ● medicines used to treat infections.
Estonian: • ravimid, mida kasutatakse infektsioonide raviks.
English: The events declined in frequency after the first month of treatment.
Estonian: Nende esinemissagedus vähenes pärast esimest ravikuud.
English: The majority of patients had no history of smoking (62%).
Estonian: Enamikel patsientidel puudus suitsetamise anamnees (62%).
English: The majority of patients had no history of smoking (70%).
Estonian: Enamikel patsientidel puudus suitsetamise anamnees (70%).
English: ● Do not take this medicine after the expiry date which is stated on the carton and either the blister or the bottle after EXP.
Estonian: • Ärge kasutage seda ravimit pärast kõlblikkusaega, mis on märgitud karbil ja blistril või pudelil pärast „Kõlblik kuni:“ (EXP).
English: They must be taken with food (see section 5.2).
Estonian: Kõvakapsleid tuleb võtta koos toiduga (vt lõik 5.2).
English: Alecensa has minor influence on the ability to drive and use machines.
Estonian: Alecensa mõjutab kergelt autojuhtimise ja masinate käsitsemise võimet.
English: The ADRs listed in Table 3 are presented by system organ class and frequency categories, defined using the following convention: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1000), very rare (<1/10,000).
Estonian: Tabelis 3 loetletud kõrvaltoimed on esitatud organsüsteemi klassi ja esinemissageduse kategooriate järgi, mille määratlemisel on kasutatud järgmist konventsiooni: väga sage (≥ 1/10), sage (≥ 1/100 kuni < 1/10), aeg-ajalt (≥ 1/1000 kuni <1/100), harv (≥ 1/10 000 kuni <1/1000), väga harv (< 1/10 000).
English: ● Do not throw away any medicines via wastewater or household waste.
Estonian: • Ärge visake ravimeid kanalisatsiooni ega olmejäätmete hulka.
English: Patients should be monitored for pulmonary symptoms indicative of pneumonitis.
Estonian: Patsiente tuleb jälgida pneumoniidile viitavate pulmonaalsete sümptomite suhtes.
English: ● Periodic safety update reports
Estonian: • Perioodilised ohutusaruanded
English: Tell your doctor straight away if you notice any of the following side effects.
Estonian: Teavitage otsekohe oma arsti, kui märkate mõnda järgmistest kõrvaltoimetest.
English: If you have been told by your doctor that you cannot tolerate or digest some sugars, talk to your doctor before taking this medicine.
Estonian: Kui arst on teile öelnud, et te ei talu või ei ole võimeline seedima teatud suhkruid, pidage enne selle ravimi võtmist nõu oma arstiga.
English: Swallow each capsule whole.
Estonian: Neelake iga kapsel alla tervelt.
English: Evaluate concomitant medicinal products known to cause bradycardia, as well as anti-hypertensive medicinal products.
Estonian: Hinnata samaaegselt kasutatavaid ravimeid, mis teadaolevalt põhjustavad bradükardiat, samuti antihüpertensiivseid ravimeid.
English: Alecensa contains lactose (a type of sugar).
Estonian: Alecensa sisaldab laktoosi (teatud tüüpi suhkur).
English: Median duration of follow-up (months)
Estonian: Järelkontrolli mediaankestus (kuud)
English: ● The active substance is alectinib.
Estonian: • Toimeaine on alektiniib.